Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Arcus Biosciences Inc's Business Segments
Arcus Biosciences Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 17
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 17 | 100% |
Revenue by Product & Service Category - Q1 FY2026
- License and development services58.8%
- Other Collaboration Revenue29.4%
- Access Rights17.6%
- R&D Services11.8%
- Other Services11.8%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| License and development services | $ 10 | 58.8% |
| Other Collaboration Revenue | $ 5 | 29.4% |
| Access Rights | $ 3 | 17.6% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
2 more categories available
Sign in to unlock the full Arcus Biosciences Inc dataset.
Description of Arcus Biosciences Inc
Arcus Biosciences Inc (NASDAQ:RCUS) is a biotechnology company that focuses on discovering and developing innovative immunotherapies to treat cancer. The company is headquartered in Hayward, California and was founded in 2015 by a team of experienced biotech executives.
Arcus Biosciences' main objective is to develop new and innovative cancer treatments that will revolutionize the way we treat this disease. The company's highly skilled team of scientists is working diligently to develop and commercialize cancer immunotherapies based on the latest advances in immunology and genomic analysis.
The company's pipeline is focused on small molecule therapies and antibodies that target key immunomodulatory pathways, with the goal of enhancing the immune system's natural ability to identify and destroy cancer cells. This approach is designed to treat a wide range of cancers, including solid tumors and hematological malignancies.
Currently, Arcus Biosciences has three clinical-stage product candidates in development, each with the potential to address a significant unmet medical need in the oncology space. The company's lead product candidate, AB928, is a small molecule dual adenosine receptor antagonist that is being evaluated in combination with chemotherapy, radiation, and other checkpoint inhibitors. The goal of this combination therapy is to enhance the anti-tumor immune response, improve the efficacy of existing cancer treatments, and improve overall patient outcomes.
Another key product in the company's pipeline is AB154, an anti-TIGIT monoclonal antibody that is being developed as a next-generation checkpoint inhibitor. This therapy is designed to block the TIGIT pathway, which plays a critical role in suppressing the immune system's natural response to cancer. The company believes that AB154 has the potential to be a highly effective therapy in combination with other cancer treatments.
The third product candidate, AB680, is a small molecule inhibitor of CD73, an enzyme that is involved in the adenosine pathway. This therapy is being evaluated in combination with other checkpoint inhibitors with the goal of enhancing the immune response against tumors and improving overall patient outcomes.
As a relatively young company, Arcus Biosciences has already made significant progress in the development of new and innovative cancer therapies. In addition to its strong product pipeline, the company has established partnerships with several other leading biotech and pharmaceutical companies, including Gilead Sciences, Roche, and Taiho Pharmaceutical. These partnerships provide the company with substantial resources and support to continue advancing its research and development efforts.
Overall, Arcus Biosciences is a highly innovative and dynamic biotechnology company that is focused on developing new and effective cancer therapies. With a strong pipeline of product candidates and a talented team of scientists and researchers, the company is well-positioned to make a profound impact in the field of oncology and improve the lives of patients affected by this devastating disease.
Arcus Biosciences' main objective is to develop new and innovative cancer treatments that will revolutionize the way we treat this disease. The company's highly skilled team of scientists is working diligently to develop and commercialize cancer immunotherapies based on the latest advances in immunology and genomic analysis.
The company's pipeline is focused on small molecule therapies and antibodies that target key immunomodulatory pathways, with the goal of enhancing the immune system's natural ability to identify and destroy cancer cells. This approach is designed to treat a wide range of cancers, including solid tumors and hematological malignancies.
Currently, Arcus Biosciences has three clinical-stage product candidates in development, each with the potential to address a significant unmet medical need in the oncology space. The company's lead product candidate, AB928, is a small molecule dual adenosine receptor antagonist that is being evaluated in combination with chemotherapy, radiation, and other checkpoint inhibitors. The goal of this combination therapy is to enhance the anti-tumor immune response, improve the efficacy of existing cancer treatments, and improve overall patient outcomes.
Another key product in the company's pipeline is AB154, an anti-TIGIT monoclonal antibody that is being developed as a next-generation checkpoint inhibitor. This therapy is designed to block the TIGIT pathway, which plays a critical role in suppressing the immune system's natural response to cancer. The company believes that AB154 has the potential to be a highly effective therapy in combination with other cancer treatments.
The third product candidate, AB680, is a small molecule inhibitor of CD73, an enzyme that is involved in the adenosine pathway. This therapy is being evaluated in combination with other checkpoint inhibitors with the goal of enhancing the immune response against tumors and improving overall patient outcomes.
As a relatively young company, Arcus Biosciences has already made significant progress in the development of new and innovative cancer therapies. In addition to its strong product pipeline, the company has established partnerships with several other leading biotech and pharmaceutical companies, including Gilead Sciences, Roche, and Taiho Pharmaceutical. These partnerships provide the company with substantial resources and support to continue advancing its research and development efforts.
Overall, Arcus Biosciences is a highly innovative and dynamic biotechnology company that is focused on developing new and effective cancer therapies. With a strong pipeline of product candidates and a talented team of scientists and researchers, the company is well-positioned to make a profound impact in the field of oncology and improve the lives of patients affected by this devastating disease.
Arcus Biosciences Inc. is at the forefront of cancer immunotherapy, employing advanced research methodologies and innovative drug development strategies to forge new paths in oncological care. The company operates within the biotechnology and healthcare sectors, featuring an integrated approach that encompasses both research and development, as well as commercialization efforts aimed at bringing its therapeutic innovations to market.
Segments
Arcus Biosciences Inc. is structured around two core segments:
1. Research and Development (R&D):
- This segment represents the heart of Arcuss operations. The company heavily invests in the discovery and development of novel cancer therapies. Leveraging sophisticated technologies such as next-generation sequencing and artificial intelligence, Arcus Biosciences innovates in biomarker identification and therapeutic design. The R&D process is characterized by rigorous preclinical studies and various phases of clinical trials to ensure comprehensive evaluation of safety and efficacy.
- The R&D segment focuses on understanding the complexities of tumor microenvironments and the immuno-suppressive mechanisms employed by tumors. This information is critical in identifying new therapeutic targets and developing drugs that can effectively engage the immune system to combat cancer.
2. Commercialization:
- While currently focused on R&D, Arcus Biosciences Inc. is proactively preparing for the commercialization of its lead products. The company aims to form strategic partnerships with established pharmaceutical companies to facilitate the distribution and marketing of its therapies once they receive regulatory approval. This segment will be vital in ensuring the broad accessibility of its innovative treatments to patients who need them the most.
Products
Arcus Biosciences Inc. has developed several promising oncology drugs, each designed to address various mechanisms of immune evasion that tumors employ. Some of the key products in their pipeline include:
1. AB928:
- A dual adenosine receptor antagonist, AB928 plays a critical role in bolstering the immune response against tumors. By blocking the adenosine receptors A2A and A2B, it aims to block adenosine-induced immune suppression, thereby enhancing T-cell activation and proliferation. Currently, AB928 is undergoing Phase II clinical trials for the treatment of multiple solid tumors, with ongoing studies focusing on its combination with other therapies to optimize patient outcomes.
2. AB680:
- AB680 is a small molecule inhibitor specifically targeting CD73, an enzyme responsible for producing adenosine in the tumor microenvironment. By inhibiting CD73, AB680 seeks to decrease adenosine levels, effectively lifting the immunosuppressive barrier that hampers immune cell activity. Currently, it is in Phase I clinical trials, targeting advanced solid tumors, gauging its safety and performance as a monotherapy and in conjunction with other agents.
3. AB122:
- This monoclonal antibody targets the PD-1 pathway, a critical immune checkpoint that many tumors exploit to evade immune detection. By blocking PD-1, AB122 aims to reinvigorate T-cell responses against cancer cells. Like AB928 and AB680, AB122 is also in Phase I clinical trials and is designed to be considered for combination therapies to enhance its effectiveness against various malignancies.
Services
In addition to drug development, Arcus Biosciences Inc. extends several essential services that support its R&D initiatives:
1. Target Discovery and Validation:
- Using cutting-edge technologies, the company facilitates the identification of potential targets for cancer therapies. This includes genomic and proteomic analyses that help uncover novel therapeutic avenues.
2. Lead Optimization:
- This process encompasses a range of scientific disciplines aimed at enhancing the potency, selectivity, and safety profile of lead compounds. The company employs various screening techniques and bioinformatics tools to refine its candidates for further development.
3. Clinical Trial Management:
- Arcus Biosciences has a robust infrastructure for the design, execution, and oversight of clinical trials. Given the complexity of modern oncological trials, the company utilizes a protocol-driven approach while ensuring compliance with regulatory standards, patient safety, and data integrity.
4. Regulatory Affairs:
- Navigating the intricate regulatory landscape is crucial for the successful launch of any biopharmaceutical product. Arcus maintains a specialized team that works closely with regulatory agencies to ensure that all aspects of drug development and clinical testing meet the required guidelines.
Conclusion
Overall, Arcus Biosciences Inc. is committed to advancing the field of cancer immunotherapy. Through its rich pipeline of promising drug candidates and comprehensive R&D capabilities, the company aims to enhance the therapeutic landscape for oncology, ultimately providing patients with novel options that harness the power of their immune systems in the fight against cancer. Each segment of Arcus—R&D and commercialization—reflects a dedication to scientific rigor and a commitment to transforming patient outcomes in oncology.
Segments
Arcus Biosciences Inc. is structured around two core segments:
1. Research and Development (R&D):
- This segment represents the heart of Arcuss operations. The company heavily invests in the discovery and development of novel cancer therapies. Leveraging sophisticated technologies such as next-generation sequencing and artificial intelligence, Arcus Biosciences innovates in biomarker identification and therapeutic design. The R&D process is characterized by rigorous preclinical studies and various phases of clinical trials to ensure comprehensive evaluation of safety and efficacy.
- The R&D segment focuses on understanding the complexities of tumor microenvironments and the immuno-suppressive mechanisms employed by tumors. This information is critical in identifying new therapeutic targets and developing drugs that can effectively engage the immune system to combat cancer.
2. Commercialization:
- While currently focused on R&D, Arcus Biosciences Inc. is proactively preparing for the commercialization of its lead products. The company aims to form strategic partnerships with established pharmaceutical companies to facilitate the distribution and marketing of its therapies once they receive regulatory approval. This segment will be vital in ensuring the broad accessibility of its innovative treatments to patients who need them the most.
Products
Arcus Biosciences Inc. has developed several promising oncology drugs, each designed to address various mechanisms of immune evasion that tumors employ. Some of the key products in their pipeline include:
1. AB928:
- A dual adenosine receptor antagonist, AB928 plays a critical role in bolstering the immune response against tumors. By blocking the adenosine receptors A2A and A2B, it aims to block adenosine-induced immune suppression, thereby enhancing T-cell activation and proliferation. Currently, AB928 is undergoing Phase II clinical trials for the treatment of multiple solid tumors, with ongoing studies focusing on its combination with other therapies to optimize patient outcomes.
2. AB680:
- AB680 is a small molecule inhibitor specifically targeting CD73, an enzyme responsible for producing adenosine in the tumor microenvironment. By inhibiting CD73, AB680 seeks to decrease adenosine levels, effectively lifting the immunosuppressive barrier that hampers immune cell activity. Currently, it is in Phase I clinical trials, targeting advanced solid tumors, gauging its safety and performance as a monotherapy and in conjunction with other agents.
3. AB122:
- This monoclonal antibody targets the PD-1 pathway, a critical immune checkpoint that many tumors exploit to evade immune detection. By blocking PD-1, AB122 aims to reinvigorate T-cell responses against cancer cells. Like AB928 and AB680, AB122 is also in Phase I clinical trials and is designed to be considered for combination therapies to enhance its effectiveness against various malignancies.
Services
In addition to drug development, Arcus Biosciences Inc. extends several essential services that support its R&D initiatives:
1. Target Discovery and Validation:
- Using cutting-edge technologies, the company facilitates the identification of potential targets for cancer therapies. This includes genomic and proteomic analyses that help uncover novel therapeutic avenues.
2. Lead Optimization:
- This process encompasses a range of scientific disciplines aimed at enhancing the potency, selectivity, and safety profile of lead compounds. The company employs various screening techniques and bioinformatics tools to refine its candidates for further development.
3. Clinical Trial Management:
- Arcus Biosciences has a robust infrastructure for the design, execution, and oversight of clinical trials. Given the complexity of modern oncological trials, the company utilizes a protocol-driven approach while ensuring compliance with regulatory standards, patient safety, and data integrity.
4. Regulatory Affairs:
- Navigating the intricate regulatory landscape is crucial for the successful launch of any biopharmaceutical product. Arcus maintains a specialized team that works closely with regulatory agencies to ensure that all aspects of drug development and clinical testing meet the required guidelines.
Conclusion
Overall, Arcus Biosciences Inc. is committed to advancing the field of cancer immunotherapy. Through its rich pipeline of promising drug candidates and comprehensive R&D capabilities, the company aims to enhance the therapeutic landscape for oncology, ultimately providing patients with novel options that harness the power of their immune systems in the fight against cancer. Each segment of Arcus—R&D and commercialization—reflects a dedication to scientific rigor and a commitment to transforming patient outcomes in oncology.